Medicus Pharma

MDCX

Market cap $11.4M

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS Newswire / March 18, 2026 / Medicus Pharma Ltd.

Phase 2 Study Demonstrated 73% clinical Clearance in the  200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.

Medicus Pharma (NASDAQ:MDCX) earlier this week highlighted encouraging data from its Phase 2 clinical trial evaluating SkinJect, a non-invasive treatment designed to address basal cell carcinoma, the most common form of skin cancer. Speaking to Proactive, chief executive Raza Bokhari said the latest dataset suggests the company's microneedle-based therapy could significantly reduce the need for surgical intervention in many patients.

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce its participation in the Longwood Miami CEO forum being held March 11-13, 2026, at the Ritz-Carlton Key Biscayne.

Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect microneedle therapy showed encouraging results in treating basal cell carcinoma, the most common form of skin cancer. The Medicus Pharma Ltd said the Phase 2 SKNJCT-003 study evaluating its SkinJect microneedle delivery system achieved 73% clinical clearance and 40% histological clearance in patients treated with a 200-microgram dose by Day 57, the strongest treatment response seen in the trial.

The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57 The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57

Medicus Pharma (NASDAQ:MDCX) CEO Dr. Raza Bokhari talked with Proactive about the company's newly reported topline Phase 2 results for its microneedle array patch technology targeting basal cell carcinoma, a common form of non-melanoma skin cancer.

Medicus Pharma Ltd. (NASDAQ: MDCX) shares surged to a high of $1.61 before falling during Thursday's premarket session following the release of topline data from its Phase 2 clinical trial for SKNJCT-003.

Medicus Pharma (NASDAQ:MDCX) said on Thursday that its experimental microneedle-based therapy showed encouraging efficacy in a mid-stage clinical trial for treating Basal Cell Carcinoma, with the highest-dose group achieving 73% clinical clearance of lesions. The Phase 2 randomized, double-blind, placebo-controlled study enrolled 90 patients with nodular basal cell carcinoma and evaluated two doses of the company's doxorubicin microneedle array (D-MNA), a non-invasive treatment designed to deliver chemotherapy through the skin.

PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce topline results from its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.